Apoptosis, mitosis, p53, bcl2, Ki-67 and clinical outcome in prostate carcinoma treated by androgen ablation

Urologia Internationalis

Volumn 63, Issue 2, 1999, Pages 115-119

  Szende, Béla ^a,d   Romics, I ^b   Torda, I ^c   Bely M ^c   Szegedi, Zs ^a   Lovasz S ^b  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c NATIONAL INSTITUTE OF RHEUMATOLOGY AND PHYSIOTHERAPY   (Hungary)

^d SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Apoptosis; Prostate carcinoma; Therapy

Indexed keywords

ANTIANDROGEN; FLUTAMIDE; KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; HISTOLOGY; HUMAN; MALE; MITOSIS; MITOSIS INDEX; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CARCINOMA; TREATMENT OUTCOME;

EID: 0032698145     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000030429     Document Type: Article

References (10)

1. Armas OA, Aprikian AG, Melamed J, Cordon-Cardo C, Cohen DW, Erlandson R, Feur WR, Reuter VE: Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Path 1994;18:979-991.
2. Dermeade SR, Lin XS, Isaacs JT: Role of programmed (apoptotic) cell death during the profession and therapy for prostate cancer. Prostate 1996;28:251-265.
3. Kyprianou N, English HF, Isaacs JT: Programmed cell death during regression of PC-81 human prostate cancer following androgen ablation. Cancer Res 1990; 50:3748-3753.
4. Montironi R, Pomante R, Diamanti L, Magi-Galluzzi C: Apoptosis in prostatic adenocarcinoma following complete androgen ablation. Urol Int 1998;60(suppl 1):25-30.
5. Szende B, Romics I, Vass L: Apoptosis in prostate cancer after hormonal treatment. Lancet 1993;342:1422.
6. Szende B, Lübben T, Romics I, Vass L: Apoptosis in untreated and hormone-treated prostate cancer of various histological types. Pathol Oncol Res 1996;2:239-241.
7. Szepesházi K, Korkut E Szende B, Lapis K, Schally AV: Histologie changes in Dunning prostate tumors and testes of rats treated with LH-RH antagonist SB-75. Prostate 1991;18: 255-270.
8. Wyllie AH, Kerr JFR, Currie AR: Cell death: The significance of apoplosis. Int Rev Cytol 1986;68:251-306.
9. Furuya Y, Walsh JC, Lin X, Nelson WG, Isaacs JT: Androgen ablation induced programmed death of prostate glandular cells does not involve recruitment into a defective cell cycle or p53 induction. Endocrinology 1995;136:1898-1906.
10. Szende B, Lübben T, Romics I, Vass L: Apoptosis in untreated and hormone-treated prostate cancer of various histological types. Path Oncol Res 1996;2:239-241.